Journal of Clinical Endocrinology & Metabolism, Vol 60, 1087-1092, Copyright © 1985 by Endocrine Society

ARTICLES

Somatomedin-C levels in children and adolescents with gonadal dysgenesis: differences from age-matched normal females and effect of chronic estrogen replacement therapy

L Cuttler, G Van Vliet, FA Conte, SL Kaplan and MM Grumbach

The factors responsible for the elevation of circulating somatomedin- C/insulin-like growth factor I (Sm-C) during normal pubertal development are uncertain. To assess the role of ovarian estrogen secretion during puberty, we examined the effect of estrogen deficiency due to primary hypogonadism on Sm-C levels in late childhood and early adolescence. The concentration of immunoreactive Sm-C was measured in 36 untreated patients with gonadal dysgenesis (age, 4-16 yr); results were compared with the pattern of change in Sm-C in 153 age-matched normal girls. Between ages 4-9 yr, patients with gonadal dysgenesis had Sm-C levels similar to those in the age-matched normal subjects. In contrast to the normal girls, Sm-C levels in patients with gonadal dysgenesis did not rise after 10 yr of age and were significantly lower than those in normal girls at 11-16 yr of age. The effect of low dose estrogen therapy was assessed in eight patients with Turner's syndrome. Their Sm-C levels were measured before and during 2-12 months of treatment with ethinyl estradiol (90-220 ng/kg X day). The mean Sm-C concentration rose from 0.72 +/- 0.06 U/ml (+/- SEM) before treatment to 1.17 +/- 0.17 U/ml during estrogen treatment (P less than 0.04). In three patients who had a similar increase in Sm-C during estrogen treatment, interruption of therapy was associated with a fall in Sm-C concentrations; when estrogen therapy was reinstituted in two of these patients, Sm-C levels rose again. These results suggest that increasing endogenous estrogen production is a major determinant of the rise of circulating Sm-C that occurs during pubertal development in normal girls. Chronic estrogen deficiency, as in untreated patients with gonadal dysgenesis, is associated with failure to manifest the elevation of Sm-C that occurs during normal puberty.

This article has been cited by other articles:

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				S. Schurgin, S. Dolan, A. Perlstein, M. P. Sullivan, N. Aliabadi, and S. Grinspoon Effects of Testosterone Administration on Growth Hormone Pulse Dynamics in Human Immunodeficiency Virus-Infected Women J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3290 - 3297. [Abstract] [Full Text] [PDF]

				T. Saaresranta and O. Polo Hormones and Breathing Chest, December 1, 2002; 122(6): 2165 - 2182. [Abstract] [Full Text] [PDF]

				C. H. Gravholt, J. Frystyk, A. Flyvbjerg, H. Orskov, and J. S. Christiansen Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E308 - E314. [Abstract] [Full Text] [PDF]

				M. E. Wilson Effects of Estradiol and Exogenous Insulin-Like Growth Factor I (IGF-I) on the IGF-I Axis during Growth Hormone Inhibition and Antagonism J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4013 - 4021. [Abstract] [Full Text]

				K. Rubin Turner Syndrome and Osteoporosis: Mechanisms and Prognosis Pediatrics, August 1, 1998; 102(2): 481 - 485. [Abstract] [Full Text]

				M. E. Wilson Regulation of the Growth Hormone-Insulin-Like Growth Factor I Axis in Developing and Adult Monkeys Is Affected by Estradiol Replacement and Supplementation with Insulin-Like Growth Factor I J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2018 - 2028. [Abstract] [Full Text]

				C. H. Gravholt, R. W. Naeraa, S. Fisker, and J. S. Christiansen Body Composition and Physical Fitness Are Major Determinants of the Growth Hormone-Insulin-Like Growth Factor Axis Aberrations in Adult Turner's Syndrome, with Important Modulations by Treatment with 17{beta}-Estradiol J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2570 - 2577. [Abstract] [Full Text] [PDF]

				A. Barreca, D. Larizza, G. Damonte, M. Arvigo, P. Ponzani, A. Cesarone, F. Lo Curto, F. Severi, G. Giordano, and F. Minuto Insulin-Like Growth Factors (IGF-I and IGF-II) and IGF-Binding Protein-3 Production by Fibroblasts of Patients with Turner's Syndrome in Culture J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1041 - 1046. [Abstract] [Full Text] [PDF]